Successful Irish applicants to Horizon 2020 Health calls – 2017

# Single-Stage Health call

|  |  |  |  |
| --- | --- | --- | --- |
| **Project Title** | **Project Acronym** | **PI Name** | **Institution/Business** |
| ERA-Net Cofund in Personalised Medicine | **ERA PerMed** | Mairead O’Driscoll | Health Research Board |
| Coach Assistant via Projected and Tangible Interface | **CAPTAIN** | Unai Diaz-Orueta | Dublin City University |
| IN-Silico trials for treatment of acute Ischemic STroke | **INSIST** |  | Neuravi Limited |
|  |  | Pat McGarry | NUI Galway |
| InSiSt: In-silico trials for drug-eluting BVS design, development and evaluation | **InSiSt** | Ted Vaughan | NUI Galway |
|  |  |  | Boston Scientific Limited |

# Two-stage health call – 2nd Stage

|  |  |  |  |
| --- | --- | --- | --- |
| **Project Title** | **Project Acronym** | **PI Name** | **Institution/Business** |
| Advancing a Precision Medicine Paradigm in metastatic Colorectal Cancer: Systems based stratification solutions | **COLOSSUS** | Annette Byrne**(Coordinator)** | RCSI |
|  |  |  | UCD |
|  |  |  | ICORG |
|  |  |  | Pintail |
| Safety and efficiency of tauroursodeoxycholic acid (TUDCA) as add-on treatment in patients affected by amyotrophic lateral sclerosis (ALS) | **TUDCA-ALS** | Orla Hardiman | TCD |
| Placenta-expanded adherent stromal cells (PLX-PAD) as an innovative therapy for improving recovery and survival following hip fracture arthroplasty – HIPGEN, a multicentre phase II trial | **HIPGEN** |  | ICON Clinical Research Limited |
| Personalised Medicine by Predictive Modeling in Stroke for better Quality of Life | **PRECISE4Q** | John Kelleher | DIT |

# SME Instrument Phase 2

|  |  |  |
| --- | --- | --- |
| **Project Title** | **Project Acronym** | **Institution/Business** |
| EASIVIRAL | **EASIVIRAL** | Altratech Limited |
| Accelerating the commercialisation of a disruptive analytical technology which enables thebiopharmaceutical industry to manufacture drugs faster, cheaper and with greater regulatory confidence | **BIOSIM** | Valitacell Ltd |